{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:22:29Z","timestamp":1793409749424,"version":"4.5.0"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>PF\u201006817024 is a high affinity, humanized antibody that binds interleukin\u201033, a proinflammatory type 2 cytokine, and thereby has the potential to inhibit downstream type 2 inflammation. This Phase 1, randomized, placebo\u2010controlled study was conducted in 3 parts to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics of escalating single and limited repeat PF\u201006817024 doses in healthy participants (Part 1), a single dose of PF\u201006817024 in participants with chronic rhinosinusitis with nasal polyps (Part 2), and repeat doses of PF\u201006817024 in participants with moderate to severe atopic dermatitis (atoptic dermatitis; Part 3). PF\u201006817024 was generally well tolerated in all participant populations. Most participants experienced a treatment\u2010emergent adverse event (healthy participants, 78.4% and 100%; participants with chronic rhinosinusitis with nasal polyps, 90.9% and 88.9%; and participants with atoptic dermatitis, 60.0% and 62.5% in the PF\u201006817024 and placebo groups, respectively). No substantial deviations from dose proportionality were observed for single intravenous doses of 10\u20101000\u00a0mg, indicating linear PK in healthy participants. Mean terminal half\u2010life ranged from 83 to 94\u00a0days after single intravenous administration in healthy participants and was similar to that observed after administration in the studied patient populations. Incidences of antidrug antibodies in the studied populations were 10.8%, 9.1%, and 5.0% for healthy participants, participants with chronic rhinosinusitis with nasal polyps, and participants with atoptic dermatitis, respectively. In addition, dose\u2010dependent increases were observed in total serum interleukin\u201033 levels of treated participants, indicating target engagement. Overall, the PK and safety profile of PF\u201006817024 supports further investigation of the drug as a potential treatment for allergic diseases.<\/jats:p>","DOI":"10.1002\/jcph.2360","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T09:14:50Z","timestamp":1695978890000},"page":"529-543","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF\u201006817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double\u2010Blind, Placebo\u2010Controlled Study"],"prefix":"10.1002","volume":"64","author":[{"given":"Spencer I.","family":"Danto","sequence":"first","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Tsamandouras","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmalatha","family":"Reddy","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean S.","family":"Beebe","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.09.015"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003331"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12552"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.09.004"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.006"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.9.5981"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301836"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-018-0464-4"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13911"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1655137"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.09.037"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13157"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2945"},{"key":"e_1_2_10_17_1","unstructured":"AnaptysBioI.AnaptysBio reports etokimab ATLAS phase 2b clinical trial in moderate\u2010to\u2010severe atopic dermatitis fails to meet primary endpoint.2019. Accessed April 26 2022.https:\/\/ir.anaptysbio.com\/news\u2010releases\/news\u2010release\u2010details\/anaptysbio\u2010reports\u2010etokimab\u2010atlas\u2010phase\u20102b\u2010clinical\u2010trial\/"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00566-2"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12547"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052433"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2015.11.002"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12567"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2341"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00475"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:00:05Z","timestamp":1713945605000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/jcph.2360"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2360","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"2022-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}